Standout Papers

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid c... 2014 2026 2018 2022 1.1k
  1. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014)
    Marcia S. Brose, Christopher M. Nutting et al. The Lancet

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 82 standout
Sub-graph 1 of 18

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Polymeric Nanoparticles for Drug Delivery
2024 Standout
15 intermediate papers

Works of István Molnár being referenced

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
2018
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
2016
and 5 more

Author Peers

Author Last Decade Papers Cites
István Molnár 555 991 185 452 43 2.0k
Marie‐Elisabeth Toubert 252 1157 131 212 61 2.2k
H. Richard Alexander 565 474 34 467 61 1.8k
T.W.J. Lennard 464 348 44 357 70 1.5k
Dapeng Li 380 278 55 754 77 1.7k
Azeez Farooki 1445 213 78 683 60 2.6k
David Nathanson 889 491 17 593 73 2.0k
Petr Starostik 829 154 300 644 82 2.7k
Katherine Liau 1082 382 119 858 36 2.0k
Patricia Wasserman 232 754 20 325 51 1.6k
Shigeto Maeda 524 645 17 530 63 1.5k

All Works

Loading papers...

Rankless by CCL
2026